Literature DB >> 6630410

Biological significance of aromatase activity in human breast tumors.

N Tilson-Mallett, S J Santner, P D Feil, R J Santen.   

Abstract

Human breast carcinomas contain aromatase, the enzyme necessary for the conversion of androgens to estrogens. If present in sufficient amounts, aromatase could catalyze the synthesis of estrogens from plasma steroid precursors and produce high breast cancer tissue concentrations. To determine the biological importance of tumor aromatase, we validated a specific and highly sensitive 3H-labeled water release assay for aromatase and used this to quantitate the amount of estrogen synthesized in vitro in breast tumors. As proof of assay validity, the [3H] water release assay detected 22.7 +/- 0.09 (+/- SEM) pmol/g . h estrogen formed vs. 24.7 pmol/g . h with the direct product isolation assay. Of 61 human breast tumors studied, 48 contained measurable aromatase activity, ranging from 5-70.5 pmol estrone formed/g . h. Three aromatase inhibitors (aminoglutethimide, testololactone, and 4-hydroxyandrostenedione) blocked this activity at concentrations similar to those affecting aromatase activity in other tissues. If biologically important, the estrogen formed locally from aromatase would be expected to stimulate production of the progesterone receptor. Under these circumstances, a positive correlation of progesterone receptor and local estrogen production should be found. In contrast, no significant correlation between aromatase activity and progesterone receptor level was observed (r = -0.27; P = NS). In addition, no correlation between estrogen receptor content and aromatase activity was detected. Finally, the amount of aromatase activity present in most tumors was insufficient to produce biologically meaningful saturation of estrogen receptors. These observations suggested that aromatase, while present in the majority of breast cancer tissues, may only be biologically important in those few tumors with very high aromatase activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6630410     DOI: 10.1210/jcem-57-6-1125

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  An aroma of complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.

Authors:  Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2013-12       Impact factor: 5.958

Review 3.  Modulation of estrogen synthesis and metabolism by phytoestrogens in vitro and the implications for women's health.

Authors:  Majorie B M van Duursen
Journal:  Toxicol Res (Camb)       Date:  2017-09-08       Impact factor: 3.524

4.  Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.

Authors:  A Lipton; R J Santen; S J Santner; H A Harvey; D White-Hershey; M J Bartholomew; F E Sharkey
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

Review 5.  Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 6.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

7.  The transdermal patches for site-specific delivery of letrozole: a new option for breast cancer therapy.

Authors:  Li Li; Xinlan Xu; Liang Fang; Yu Liu; Yinghua Sun; Mangli Wang; Nanxi Zhao; Zhonggui He
Journal:  AAPS PharmSciTech       Date:  2010-06-26       Impact factor: 3.246

8.  Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.

Authors:  T Zaccheo; E Di Salle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4).

Authors:  Fanfan Zhou; Ling Zhu; Pei H Cui; W Bret Church; Michael Murray
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

Review 10.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.